\documentclass[11pt,letterpaper]{report}
\usepackage{scientific_report}

\begin{document}
% Your content here
\end{document}

xelatex document.tex

\begin{keyfindings}[Research Highlights]
Our analysis revealed three significant findings:
\begin{enumerate}
    \item Treatment A was 40% more effective than control (\pvalue{0.001})
    \item Effect sizes were clinically meaningful (\effectsize{d}{0.82})
    \item Benefits persisted at 12-month follow-up
\end{enumerate}
\end{keyfindings}

\begin{methodology}[Study Design]
This double-blind, randomized controlled trial employed a 2×2 factorial
design. Participants (\samplesize{450}) were randomized to one of four
conditions: (1) Treatment A, (2) Treatment B, (3) Combined A+B, or
(4) Placebo control.
\end{methodology}

\begin{resultsbox}[Primary Outcome Analysis]
Mixed-effects regression revealed a significant treatment × time
interaction, \effectsize{F(3, 446)}{8.72}, \psig{< 0.001},
$\eta^2_p$ = 0.055, indicating differential improvement across
treatment conditions over the study period.
\end{resultsbox}

\begin{recommendations}[Clinical Practice Guidelines]
Based on our findings, we recommend:
\begin{enumerate}
    \item \textbf{Primary recommendation:} Implement screening protocol
        for high-risk populations.
    \item \textbf{Secondary recommendation:} Adjust treatment intensity
        based on baseline severity scores.
    \item \textbf{Monitoring:} Reassess at 3-month intervals.
\end{enumerate}
\end{recommendations}

\begin{limitations}[Study Limitations]
Several limitations should be considered:
\begin{itemize}
    \item \textbf{Sample:} Participants were recruited from academic
        medical centers, limiting generalizability to community settings.
    \item \textbf{Design:} The observational design precludes causal
        inference about treatment effects.
    \item \textbf{Attrition:} 15% dropout rate may introduce bias.
\end{itemize}
\end{limitations}

\begin{criticalnotice}[Safety Warning]
\textbf{Contraindication:} This intervention is contraindicated for
patients with [condition]. Monitor for [adverse effects] and discontinue
immediately if [symptoms] occur. Report serious adverse events to [contact].
\end{criticalnotice}

\begin{definition}[Effect Size]
An \textbf{effect size} is a quantitative measure of the magnitude of a
phenomenon. Unlike significance tests, effect sizes are independent of
sample size and allow comparison across studies. Common measures include
Cohen's \textit{d} for mean differences and Pearson's \textit{r} for
correlations.
\end{definition}

\begin{table}[htbp]
\centering
\caption{Demographic Characteristics by Treatment Group}
\label{tab:demographics}
\begin{tabular}{@{}lcc@{}}
\toprule
\textbf{Characteristic} & \textbf{Treatment} & \textbf{Control} \\
 & (\samplesize{225}) & (\samplesize{225}) \\
\midrule
Age, years, \meansd{M}{SD} & \meansd{42.3}{12.5} & \meansd{43.1}{11.8} \\
\rowcolor{tablealt} Female, n (\%) & 128 (56.9) & 121 (53.8) \\
Education, years, \meansd{M}{SD} & \meansd{14.2}{2.8} & \meansd{14.5}{2.6} \\
\rowcolor{tablealt} Baseline score, \meansd{M}{SD} & \meansd{52.4}{15.3} & \meansd{51.8}{14.9} \\
\bottomrule
\end{tabular}
\figurenote{No significant differences between groups at baseline (all \textit{p} > .10).}
\end{table}

\begin{table}[htbp]
\centering
\caption{Treatment Effects on Primary and Secondary Outcomes}
\label{tab:results}
\begin{tabular}{@{}lcccc@{}}
\toprule
\textbf{Outcome} & \textbf{Treatment} & \textbf{Control} & \textbf{Effect} & \textbf{p} \\
 & \meansd{M}{SD} & \meansd{M}{SD} & \textbf{(d)} & \\
\midrule
Primary outcome & \meansd{68.4}{14.2} & \meansd{54.1}{15.8} & 0.95\sigthree & <.001 \\
\rowcolor{tablealt} Secondary A & \meansd{4.2}{1.1} & \meansd{3.5}{1.2} & 0.61\sigtwo & .003 \\
Secondary B & \meansd{22.8}{5.4} & \meansd{21.2}{5.1} & 0.31\sigone & .042 \\
\rowcolor{tablealt} Secondary C & \meansd{8.9}{2.3} & \meansd{8.5}{2.4} & 0.17\signs & .285 \\
\bottomrule
\end{tabular}

\vspace{0.5em}
{\small \siglegend}
\end{table}

\begin{table}[htbp]
\centering
\caption{Evidence Summary by Study}
\label{tab:evidence}
\begin{tabular}{@{}llccc@{}}
\toprule
\textbf{Study} & \textbf{Design} & \textbf{N} & \textbf{Quality} & \textbf{Evidence} \\
\midrule
Smith et al. (2024) & RCT & 450 & \qualityhigh & \evidencestrong \\
\rowcolor{tablealt} Jones et al. (2023) & Cohort & 1,250 & \qualitymedium & \evidencemoderate \\
Chen et al. (2023) & Case-control & 320 & \qualitymedium & \evidencemoderate \\
\rowcolor{tablealt} Lee et al. (2022) & Cross-sectional & 890 & \qualitylow & \evidenceweak \\
\bottomrule
\end{tabular}
\end{table}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{../figures/results_comparison.png}
\caption{Comparison of Outcome Scores by Treatment Condition and Time Point}
\label{fig:results}
\end{figure}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.85\textwidth]{../figures/trend_analysis.png}
\caption{Trends in Key Metrics Over the Study Period}
\figuresource{Study data collected January--December 2024}
\label{fig:trends}
\end{figure}

\begin{figure}[htbp]
\centering
\includegraphics[width=0.8\textwidth]{../figures/conceptual_model.png}
\caption{Conceptual Model of Hypothesized Relationships}
\figurenote{Solid arrows indicate primary pathways; dashed arrows indicate moderated relationships. Numbers represent standardized coefficients.}
\label{fig:model}
\end{figure}

\chapter*{Executive Summary}
\addcontentsline{toc}{chapter}{Executive Summary}

\begin{executivesummary}[Report Highlights]
This report presents findings from a comprehensive study of [topic]
involving \samplesize{450} participants across 12 research sites.
The research addressed [key question] using [methodology].
\end{executivesummary}

\subsection*{Key Findings}

\begin{keyfindings}
\begin{enumerate}
    \item The primary intervention demonstrated a large effect
          (\effectsize{d}{0.82}, \psig{< 0.001}).
    \item Benefits were maintained at 12-month follow-up.
    \item Cost-effectiveness analysis supports implementation.
\end{enumerate}
\end{keyfindings}

\subsection*{Recommendations}

\begin{recommendations}
Based on these findings, we recommend:
\begin{enumerate}
    \item Implement the intervention in [settings].
    \item Train practitioners using the standardized protocol.
    \item Monitor outcomes using the validated measures.
\end{enumerate}
\end{recommendations}

\chapter{Methods}

\begin{methodology}[Study Overview]
This randomized controlled trial employed a parallel-group design with
1:1 allocation to intervention or control conditions. The study was
conducted across 12 sites between January 2023 and December 2024.
\end{methodology}

\section{Participants}

A total of \samplesize{450} participants were enrolled. Eligibility
criteria were:

\begin{itemize}
    \item Age 18--65 years
    \item Diagnosis of [condition] per [criteria]
    \item No contraindications to [intervention]
\end{itemize}

Table~\ref{tab:participants} presents participant characteristics.

\begin{limitations}[Recruitment Challenges]
Recruitment was slower than anticipated due to [reasons]. The final
sample was 10% below target, which may affect statistical power for
secondary analyses.
\end{limitations}

\chapter{Results}

\section{Primary Outcome}

\begin{resultsbox}[Primary Analysis]
Mixed-effects regression revealed a significant treatment effect,
\effectsize{F(1, 448)}{42.18}, \psig{< 0.001}, with a large effect
size (\effectsize{d}{0.82}). The treatment group showed significantly
greater improvement (\meansd{16.4}{5.2} points) compared to control
(\meansd{8.1}{4.8} points).
\end{resultsbox}

Figure~\ref{fig:primary} illustrates the treatment effects over time.

\begin{figure}[htbp]
\centering
\includegraphics[width=0.9\textwidth]{../figures/primary_outcome.png}
\caption{Primary Outcome Scores by Treatment Group and Time Point}
\figurenote{Error bars represent 95\% confidence intervals.}
\label{fig:primary}
\end{figure}

\section{Secondary Outcomes}

Results for secondary outcomes are presented in Table~\ref{tab:secondary}.

\chapter{Discussion}

\section{Summary of Findings}

\begin{keyfindings}[Main Conclusions]
\begin{enumerate}
    \item The intervention was highly effective (primary hypothesis
          \highlight{supported})
    \item Effects were clinically meaningful and durable
    \item Evidence strength: \evidencestrong
\end{enumerate}
\end{keyfindings}

\section{Limitations}

\begin{limitations}
Several limitations warrant consideration:
\begin{itemize}
    \item The sample was predominantly [demographic], limiting
          generalizability.
    \item Attrition was higher in the control group (18\% vs. 12\%).
    \item Self-report measures may be subject to response bias.
\end{itemize}
\end{limitations}

\section{Implications}

\begin{recommendations}[Research Implications]
\begin{enumerate}
    \item Replicate in diverse populations
    \item Investigate mechanisms of change
    \item Test implementation strategies
\end{enumerate}
\end{recommendations}

\begin{recommendations}[Practice Implications]
\begin{enumerate}
    \item Adopt the intervention in [settings]
    \item Train providers using standardized protocols
    \item Monitor fidelity and outcomes
\end{enumerate}
\end{recommendations}